Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...

Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...

Research analysts at William Blair upped their FY2025 EPS estimates for shares of ABM Industries in a report issued on ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

Palantir (NASDAQ:PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...